论文部分内容阅读
目的:探讨三磷酸腺苷结合转运蛋白G超家族成员2(ATP-Binding cassette transporter group 2,ABCG2)在肾细胞癌(RCC)临床随访中的意义。方法:从本院肾癌数据库中选择具有完整资料的RCC组织标本110例,患者年龄(56±10)岁(17~80岁),随访时间为(72±30)个月(6~102个月)。以10例肾积水失功能的无癌肾组织为对照。使用ABCG2标准试剂盒对所有组织标本进行免疫组织化学染色,并结合临床、病理参数进行回归分析。结果:在110例RCC组织中,62例(56.4%)ABCG2呈阳性表达;在10例非肾癌组织中,ABCG2均呈阴性表达(P<0.01)。RCC组织中ABCG2的表达水平与远处转移和5年存活率密切相关(P<0.05)。RCC患者5年总生存率为79.1%,其中ABCG2阴性者为93.8%,ABCG2阳性者为67.7%(P<0.001),两组总生存时间分别为(85.1±22.7)个月和(62.1±32.8)个月(P<0.001)。Cox多因素回归分析显示ABCG2是总生存时间的独立预后因子,相对危险度(risk ratio,RR)为2.846(P<0.01)。结论:ABCG2的表达水平与RCC患者是否有远处转移及5年生存率密切相关,且ABCG2表达越强,RCC患者的预后越差。ABCG2是RCC的独立预后指标,推荐其可作为临床常规随访项目之一。
Objective: To investigate the significance of ATP-Binding cassette transporter group 2 (ABCG2) in the follow-up of renal cell carcinoma (RCC). Methods: Totally 110 RCC tissues with complete data were selected from our renal cell carcinoma database. The patients were 56 ± 10 years old (17 to 80 years old) and followed up for 72 ± 30 months (6 to 102 months) month). Ten cases of hydronephrosis without function of renal cancer as a control. Immunohistochemical staining was performed on all tissue samples using ABCG2 standard kit, and regression analysis was performed based on clinical and pathological parameters. RESULTS: ABCG2 was positive in 62 cases (56.4%) of 110 RCC tissues, and negative in ABCG2 (P <0.01) in 10 cases of non-renal cancer tissues. The expression of ABCG2 in RCC tissues was closely related to the distant metastasis and 5-year survival rate (P <0.05). The 5-year overall survival rate was 79.1% in RCC patients, 93.8% in ABCG2-negative patients and 67.7% in ABCG2-positive patients (P <0.001). The overall survival was (85.1 ± 22.7) months and (62.1 ± 32.8) ) Months (P <0.001). Cox regression analysis showed that ABCG2 was an independent prognostic factor of overall survival, with a relative risk (RR) of 2.846 (P <0.01). Conclusion: The expression of ABCG2 is closely related to whether there is distant metastasis and 5-year survival rate in patients with RCC. The stronger the expression of ABCG2, the worse the prognosis of patients with RCC. ABCG2 is an independent prognostic indicator of RCC and is recommended as one of the clinical follow-up items.